Global market valuation was derived through revenue mapping, production volume analysis, and retail sales tracking. The methodology included:
• Identification of 50+ key manufacturers and brands across North America, Europe, Asia-Pacific, and Latin America specializing in full-spectrum, broad-spectrum, and CBD isolate formulations
• Product mapping across hemp-derived and marijuana-derived CBD oil categories, segmented by concentration levels (low <5%, medium 5-15%, high >15% CBD content)
• Distribution channel analysis covering B2B wholesale, direct-to-consumer e-commerce, retail brick-and-mortar, hospital pharmacies, and medical dispensaries
• End-use application segmentation across chronic pain management, mental health disorders (anxiety/depression), cancer supportive care, general wellness, personal care & cosmetics, food & beverages, and pharmaceutical APIs
• Analysis of reported and modeled annual revenues specific to CBD hemp oil portfolios, including white-label and private label manufacturing revenues
• Coverage of manufacturers and cultivators representing 75-80% of global market share in 2024
• Extrapolation using bottom-up (cultivation volume × extraction yield × price per liter by region × distribution channel markup) and top-down (manufacturer revenue validation against retail scanner data) approaches to derive segment-specific valuations for wellness, pharmaceuticals, nutraceuticals, and personal care verticals